These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7663658)

  • 21. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
    Hodson M
    Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
    Homnick DN; Marks JH; Rubin BK
    J Aerosol Med; 2007; 20(1):45-9. PubMed ID: 17388752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [rhDNase: scientific background, cloning and production].
    Shak S
    Arch Pediatr; 1995 Jul; 2(7):666-9. PubMed ID: 7663657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Numerical and experimental investigation of mucociliary clearance breakdown in cystic fibrosis.
    Chatelin R; Anne-Archard D; Murris-Espin M; Thiriet M; Poncet P
    J Biomech; 2017 Feb; 53():56-63. PubMed ID: 28117099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
    Dasgupta B; Brown NE; King M
    Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of drugs on mucus clearance.
    Houtmeyers E; Gosselink R; Gayan-Ramirez G; Decramer M
    Eur Respir J; 1999 Aug; 14(2):452-67. PubMed ID: 10515429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model of mucociliary clearance in cystic fibrosis lungs.
    Kurbatova P; Bessonov N; Volpert V; Tiddens HA; Cornu C; Nony P; Caudri D;
    J Theor Biol; 2015 May; 372():81-8. PubMed ID: 25746843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients.
    Deneuville E; Perrot-Minot C; Pennaforte F; Roussey M; Zahm JM; Clavel C; Puchelle E; de Bentzmann S
    Am J Respir Crit Care Med; 1997 Jul; 156(1):166-72. PubMed ID: 9230742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucus structure and properties in cystic fibrosis.
    Rubin BK
    Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
    Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
    Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis.
    Amin N; Dozor AJ
    Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheological and transport properties of airway secretions in cystic fibrosis--relationships with the degree of infection and severity of the disease.
    Puchelle E; Jacquot J; Beck G; Zahm JM; Galabert C
    Eur J Clin Invest; 1985 Dec; 15(6):389-94. PubMed ID: 3938409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials of recombinant human DNase in cystic fibrosis patients.
    Aitken ML
    Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New pharmacological approaches: rhDNase].
    Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
    Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.
    Minasian C; Wallis C; Metcalfe C; Bush A
    Thorax; 2010 Jan; 65(1):51-6. PubMed ID: 19996349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
    Shibuya Y; Wills PJ; Cole PJ
    Respirology; 2003 Jun; 8(2):181-5. PubMed ID: 12753533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is cystic fibrosis mucus abnormal?
    King M
    Pediatr Res; 1981 Feb; 15(2):120-2. PubMed ID: 7254936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.